OncoCyte (LTS:0KCC) Other Gross PPE : $1.64 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Other Gross PPE?

OncoCyte's Other Gross PPE for the quarter that ended in Dec. 2023 was $1.64 Mil.

OncoCyte's quarterly Other Gross PPE declined from Jun. 2023 ($1.89 Mil) to Sep. 2023 ($1.76 Mil) and declined from Sep. 2023 ($1.76 Mil) to Dec. 2023 ($1.64 Mil).

OncoCyte's annual Other Gross PPE increased from Dec. 2021 ($1.54 Mil) to Dec. 2022 ($2.18 Mil) but then declined from Dec. 2022 ($2.18 Mil) to Dec. 2023 ($1.64 Mil).

OncoCyte Other Gross PPE Historical Data

The historical data trend for OncoCyte's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Other Gross PPE Chart

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

2.86

3.40

1.54

2.18

1.64

OncoCyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Gross PPE	Get a 7-Day Free Trial															2.18	2.02	1.89	1.76	1.64

OncoCyte Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

OncoCyte (LTS:0KCC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (LTS:0KCC) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

OCX:USA

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (LTS:0KCC) Headlines

No Headlines